id	author	title	date	pages	extension	mime	words	sentence	flesch	summary	cache	txt
cord-348501-8cvtqj7w	Beyzaee, Amir Mohammad	Rituximab as the treatment of pemphigus vulgaris in the COVID‐19 pandemic era: A narrative review	2020-10-20		.txt	text/plain	2513	99	33	Although evidence for treating PV patients with rituximab in COVID-19 pandemic is limited, and outcomes of MS patients taking rituximab was controversial, until sufficient evidence as a guideline for pemphigus and COVID-19 treatment is available, we advocate caution commencing rituximab for pemphigus patients and adherence to basic principles of infection control and decreasing drug induced immunosuppression as possible. 28 High amount of IL-6, a strong factor related to mortality in COVID-19 patients, is seen in patients given rituximab and secukinumab, that can be due to the failure of rituximab and secukinumab to modulate IL-6.	cache/cord-348501-8cvtqj7w.txt	txt/cord-348501-8cvtqj7w.txt
